797619.fig.003a
(a)
797619.fig.003b
(b)
797619.fig.003c
(c)
797619.fig.003d
(d)
797619.fig.003e
(e)
797619.fig.003f
(f)
Figure 3: Effects of oral gefitinib on the tumor volume and BRAK or BMAC mRNA level. HNSCC cells (1 107) of lines HSC-2 (a), HSC-3 (b), HSC-4 (c), and YCU-H891 (d) were subcutaneously injected separately into both flanks of 10 female athymic nude mice and allowed to form a tumor burden for 10 days. The mice were daily-administered oral gefitinib (50 mg/kg/day). Tumor volume was measured daily. In some mice treated with gefitinib for 4 days, tumor tissues or host organs were taken to extract total RNA. Human CXCL14/BRAK or mouse BMAC mRNA expressions in transplants (e) and host organs (f) were determined by RT-PCR. PCR products were visualized by ethidium bromide staining after electrophoresis in 1.5% agarose gel. Arrows indicate time-point of administration of gefitinib. ** (Student’s t-test); values are expressed as the mean SD ( ) (Cited from [3]).